The Scientist - Home

So far, the bulk of the identified water molecules are too distant from one another to form ice or liquid.

Bat species use different strategies to dampen immune activation in response to viruses.

Recent data show that the drug bamlanivimab, also known as LY-CoV555, does not appear to help those with severe cases of COVID-19, but trials continue for milder cases.

Repeat COVID-19 cases could offer clues about people’s immunity to the novel coronavirus and how to vaccinate against it.

The decision comes after Purdue Pharma, founded by the Sackler family, announced it would plead guilty to federal criminal charges for its role in the opioid epidemic.

If approved, Proposition 14 would authorize the state to sell $5.5 billion in bonds to extend the life of CIRM, which funds stem cell research. The ballot measure has its critics.

Sapan Desai has inactivated his license in Illinois, where multiple malpractice lawsuits against him are pending, and obtained a new one in Ohio.

Government leaders claim the reductions are necessary to free up assets to deal with COVID-19 and address corruption in research.

Researchers detail how viral proteins interact with host RNA to disrupt the cell’s ability to fight back against infection.

The agreement will enable authors at eligible German institutes to publish an estimated 400 open-access papers each year in Springer Nature journals from the Nature line of titles.

The findings may have implications for radiotherapy, a cancer treatment that can cause damage to salivary glands and leave lasting complications.

Conservation biologist John Ewen discusses the recent reintroduction of Tasmanian devils to mainland Australia after a 3,000-year absence and issues that need to be considered when bringing long-departed animals back into an area.